Valuation: Galapagos NV

Market Cap 1.61B 1.84B 1.84B 1.5B 1.38B 2.59B 177B 2.63B 17.83B 6.97B 87.03B 6.9B 6.75B 301B P/E 2026 *
-11.5x
P/E 2027 * -8.68x
Enterprise Value -369M -420M -420M -343M -315M -591M -40.44B -600M -4.07B -1.59B -19.88B -1.58B -1.54B -68.74B EV / Sales 2026 *
-25.9x
EV / Sales 2027 * -8.22x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 11/05/2025
Director of Finance/CFO 41 06/07/2025
Chief Operating Officer - 31/05/2026
Director TitleAgeSince
Director/Board Member 63 21/10/2019
Director/Board Member 49 06/10/2024
Director/Board Member 53 11/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
+1.07%-3.49%-3.25%+12.87% 46.86B
+0.25%+1.65%+408.41%+629.49% 40.23B
-0.27%+4.45%+9.93%+66.92% 36.23B
+0.35%+0.87%+3.60%-8.81% 34.72B
+3.14%+1.02%+3.37%+38.15% 27.89B
-0.73%+11.84%+31.97%+143.53% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%+0.76%+8.50% 13.12B
-2.68%-2.49%-15.00%-31.68% 12.7B
Average +0.22%+0.83%+54.97%+107.37% 27.25B
Weighted average by Cap. +0.48%+0.91%+75.32%+136.64%

Financials

2026 *2027 *
Net sales 14.24M 16.21M 16.21M 13.24M 12.15M 22.83M 1.56B 23.19M 157M 61.44M 768M 60.87M 59.55M 2.65B 46.09M 52.47M 52.47M 42.86M 39.33M 73.9M 5.05B 75.04M 509M 199M 2.48B 197M 193M 8.59B
Net income -811M -923M -923M -754M -692M -1.3B -88.89B -1.32B -8.95B -3.5B -43.7B -3.47B -3.39B -151B -238M -271M -271M -221M -203M -381M -26.07B -387M -2.63B -1.03B -12.82B -1.02B -994M -44.32B
Net Debt -1.98B -2.26B -2.26B -1.84B -1.69B -3.18B -217B -3.23B -21.9B -8.56B -107B -8.48B -8.29B -370B -1.99B -2.27B -2.27B -1.85B -1.7B -3.2B -219B -3.25B -22.02B -8.6B -107B -8.52B -8.34B -372B
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B